|
1.
|
Harris SL and Levine AJ: The p53 pathway:
positive and negative feedback loops. Oncogene. 24:2899–2908. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Hollstein M, Sidransky D, Vogelstein B and
Harris CC: p53 mutations in human cancers. Science. 253:49–53.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Ventura A, Kirsch DG, McLaughlin ME, et
al: Restoration of p53 function leads to tumour regression in vivo.
Nature. 445:661–665. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Rother K, Kirschner R, Sanger K, Bohlig L,
Mossner J and Engeland K: p53 downregulates expression of the G1/S
cell cycle phosphatase Cdc25A. Oncogene. 26:1949–1953. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Yu J and Zhang L: The transcriptional
targets of p53 in apoptosis control. Biochem Biophys Res Commun.
331:851–858. 2005. View Article : Google Scholar
|
|
6.
|
Xue W, Zender L, Miething C, et al:
Senescence and tumour clearance is triggered by p53 restoration in
murine liver carcinomas. Nature. 445:656–660. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Crighton D, Wilkinson S, O’Prey J, et al:
DRAM, a p53-induced modulator of autophagy, is critical for
apoptosis. Cell. 126:121–134. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Boehme KA and Blattner C: Regulation of
p53 - insights into a complex process. Crit Rev Biochem Mol Biol.
44:367–392. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Piette J, Neel H and Marechal V: Mdm2:
keeping p53 under control. Oncogene. 15:1001–1010. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Wu X, Bayle JH, Olson D and Levine AJ: The
p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7:1126–1132.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Hock A and Vousden KH: Regulation of the
p53 pathway by ubiquitin and related proteins. Int J Biochem Cell
Biol. 42:1618–1621. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Marine JC and Jochemsen AG: Mdmx as an
essential regulator of p53 activity. Biochem Biophys Res Commun.
331:750–760. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Wiman KG: Strategies for therapeutic
targeting of the p53 pathway in cancer. Cell Death Differ.
13:921–926. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Bond GL, Hu W and Levine AJ: MDM2 is a
central node in the p53 pathway: 12 years and counting. Curr Cancer
Drug Targets. 5:3–8. 2005.PubMed/NCBI
|
|
15.
|
Vassilev LT, Vu BT, Graves B, et al: In
vivo activation of the p53 pathway by small-molecule antagonists of
MDM2. Science. 303:844–848. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Hu B, Gilkes DM, Farooqi B, Sebti SM and
Chen J: MDMX overexpression prevents p53 activation by the MDM2
inhibitor Nutlin. J Biol Chem. 281:33030–33035. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Toledo F and Wahl GM: MDM2 and MDM4: p53
regulators as targets in anticancer therapy. Int J Biochem Cell
Biol. 39:1476–1482. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Hu B, Gilkes DM and Chen J: Efficient p53
activation and apoptosis by simultaneous disruption of binding to
MDM2 and MDMX. Cancer Res. 67:8810–8817. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Wu SP, Fu AL, Wang YX, et al: A novel
therapeutic approach to 6-OHDA-induced Parkinson’s disease in rats
via supplementation of PTD-conjugated tyrosine hydroxylase. Biochem
Biophys Res Commun. 346:1–6. 2006.
|
|
20.
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Bottger A, Bottger V, Garcia-Echeverria C,
et al: Molecular characterization of the hdm2-p53 interaction. J
Mol Biol. 269:744–756. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Momand J, Zambetti GP, Olson DC, George D
and Levine AJ: The mdm-2 oncogene product forms a complex with the
p53 protein and inhibits p53-mediated transactivation. Cell.
69:1237–1245. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Zifou JT and Lowe SW: Tumor suppressive
function of p53. Cold Spring Harb Perspect Biol.
1:a0018832009.PubMed/NCBI
|
|
24.
|
Fischer U and Schulze-Osthoff K: New
approaches and therapeutics targeting apoptosis in disease.
Pharmacol Rev. 57:187–215. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Roth JA, Nguyen D, Lawrence DD, et al:
Retrovirus-mediated wild-type p53 gene transfer to tumors of
patients with lung cancer. Nat Med. 2:985–991. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Clayman GL, el-Naggar AK, Lippman SM, et
al: Adenovirus-mediated p53 gene transfer in patients with advanced
recurrent head and neck squamous cell carcinoma. J Clin Oncol.
16:2221–2232. 1998.PubMed/NCBI
|
|
27.
|
Swisher SG, Roth JA, Nemunaitis J, et al:
Adenovirus-mediated p53 gene transfer in advanced non-small-cell
lung cancer. J Natl Cancer Inst. 91:763–771. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Ritter T, Lehmann M and Volk HD:
Improvements in gene therapy: averting the immune response to
adenoviral vectors. BioDrugs. 16:3–10. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
McEvoy J, Ulyanov A, Brennan R, et al:
Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA
splicing and protein expression in retinoblastoma. PLoS One.
7:e427392012. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Patton JT, Mayo LD, Singhi AD, Gudkov AV,
Stark GR and Jackson MW: Levels of HdmX expression dictate the
sensitivity of normal and transformed cells to Nutlin-3. Cancer
Res. 66:3169–3176. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Wade M, Wong ET, Tang M, Stommel JM and
Wahl GM: Hdmx modulates the outcome of p53 activation in human
tumor cells. J Biol Chem. 281:33036–33044. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Francoz S, Froment P, Bogaerts S, et al:
Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating
and quiescent cells in vivo. Proc Natl Acad Sci USA. 103:3232–3237.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Toledo F, Krummel KA, Lee CJ, et al: A
mouse p53 mutant lacking the proline-rich domain rescues Mdm4
deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory
network. Cancer Cell. 9:273–285. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Stommel JM and Wahl GM: A new twist in the
feedback loop: stress-activated MDM2 destabilization is required
for p53 activation. Cell Cycle. 4:411–417. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Cai X and Yuan ZM: Stochastic modeling and
simulation of the p53-MDM2/MDMX loop. J Comput Biol. 16:917–933.
2009. View Article : Google Scholar : PubMed/NCBI
|
